GENE

Genetic Technologies Limited (GENE) | Rumor.io

Genetic Technologies

GENE

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about GENE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 12

Genetic Technologies Limited (GENE) has a top analyst price target for next week.
The stock has been experiencing buying interest, with some users hoping to catch a knife or flip the stock for a quick profit.
Concerns have been raised about the company's financial health, with some users noting that it has barely $1.8m in cash and that offering holders may have taken short positions.

Generated by AI

Sentiment

Of the messages about GENE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +25.89
Bearish	—	—	—	0% -25.89

Bullish· Sep 12

$GENE has a strong partnership with AMD, providing a solid backing for the company.
The company's genetic testing services, such as its geneType Breast Cancer Risk Assessment Test, have demonstrated improved performance compared to the current golden standard.
$GENE has a strong financial position, with $7.9M in cash, 47% Gross Margin, and no debt, which could support its growth and expansion.

Bearish· Feb 9

$GENE is experiencing a significant sell-off, with shorts desperate to exit the market.
The company's notorious for squeezing after hours or pre-market, suggesting a potential trap for investors.
$GENE's price has disappointed, with a pop to $2.10+ during pre-market followed by a decline, indicating a lack of sustained momentum.

Generated by AI

Topics

Of the messages about GENE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	70%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	30%

Announcements· Feb 9

Genetic Technologies Limited ($GENE) announced a new publication highlighting its GeneType test's ability to detect breast cancer earlier and provide data for risk stratification.
The company will launch a "World First" Comprehensive Risk Assessment Test, which evaluates a woman's risk of developing breast and/or ovarian cancer, and will be distributed via QIAGEN's network.
Genetic Technologies shares surged 23% premarket after validating early breast cancer detection of its diagnostic test, with the company's stock price reaching $1.79.

Technical Analysis· Feb 9

The $GENE stock is setting up for a potential cup and handle formation on the 5-minute chart, with a possible bullish run to $3.
The stock has been accumulating bullish patterns over the past two weeks, with a catalyst news from Biden on Cancer research, and has been preparing for a monster run.
The break above $2 is expected to be a significant event, with the potential for a nasty move, and the stock is setting up for a round 2, with the need to hold the $1.70-$1.75 area and push over VWAP.

Generated by AI

Community

Of the messages about GENE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0%
Newcomers	—	—	—	100%

Regulars· Feb 9

The company's GeneType test has shown the ability to detect breast cancer earlier, with a study suggesting that if women with stage 2 and above breast cancer had been assessed with GeneType, they could have been diagnosed with earlier stage cancer.
GeneType has been shown to outperform 5-year and remaining lifetime risk prediction compared to commonly used clinical models Gail and IBISv7, respectively.
The company's stock surged ~20% after a study suggested that GeneType tests detect breast cancer earlier, with the stock price currently looking to break through the $1.95 level.

Newcomers· Feb 9

Newcomers are warning about taking trades under the Volume-Weighted Average Price (VWAP) due to perceived risk.
The asset has disappointed with a drop in price, despite an earlier increase to $2.10+ during the PM session.
There is excitement about a potential 10-15x increase in value when the DeSci trend kicks in, possibly in the next month or two.

Generated by AI

Also Discussed

Investors talking about GENE also mention

#	Name	Attention
1	Oncolytics Biotech Inc.ONCY	0%0
2	Gulf Resources, Inc.GURE	0%new
3	Can-Fite BioPharma Ltd. ADRCANF	0%0
4	XOMA CorporationXOMA	0%0
5	iBio, Inc.IBIO	0%0
6	ABIO - ARCA biopharma, Inc.	——
7	Live Ventures IncorporatedLIVE	0%0
8	Edap Tms S.A.EDAP	0%0
9	Coda Octopus Group, Inc.CODA	0%0
10	PeakShares Sector Rotation ETFPSTR	0%new